Wholeleaf Bolsters PanIndia Retail Expansion Targets 7000 Outlets in Key Markets
Morgan Stanley Lowers Southern Company Price Target Cites Potential Utilities Sector Underperformance
Canadas Big Banks Expected to Report Solid Q2 Earnings but Outlook Takes Center Stage Amid Softening Economy
Caribbean Real Estate Dispute Foreign Buyers and Beach Access Concerns in Barbuda Grenada and Jamaica
Markets SixWeek Record Run Top and Bottom Performers in the Club Portfolio
Tony Blairs Economic Diagnosis for UK Gains Traction but AI Prescription Draws Skepticism
WDS Q4 2025 Earnings EPS Surges 338 Above Estimates on Strong Operational Performance
CCEL Q1 2026 Earnings Earnings Beat Expectations with Positive EPS
CWK Q1 2026 Earnings EPS Beats Estimates by 114 Amid Mixed Market Reaction
Koppers Holdings KOP Q1 2026 Earnings EPS Surges Past Estimates on Strong Operational Performance
Orion Energy Systems Inc OESX Q1 2026 Earnings Strong Profitability Surprise Amid Thin Revenue Disclosure
CAKE Q1 2026 Earnings Modest EPS Beat Amidst Cautious Consumer Environment
Phunware PHUN Stock Rises Nearly 2 as Shares Test Key Resistance Area
Psyence Biomedical Warrants PBMWW Edge Higher Support and Resistance Converge at 003
Calamos Convertible and High Income Fund CHY Nears Key Support After Minimal Change
Daedalus Special Acquisition Corp DSAC Holds Steady Near Trust Value as MA Speculation Builds
Abony Acquisition Corp I Units AACOU Holds Near 10 as SPAC Trades Tightly
NNI Q1 2026 Earnings EPS Misses Estimates by 2782
Research Solutions RSSS Q1 2026 Earnings EPS Misses Estimates Amid Modest Share Decline
FB Financial Q1 2026 Earnings Slight EPS Miss Meets Modest Stock Gains
XPER Q1 2026 Earnings Strong EPS Beat Drives Stock Higher
ECCC Q4 2025 Earnings Preferred Stock Delivers EPS Beat Amid Stable Portfolio Performance
CubeSmart Q1 2026 Earnings Slight EPS Beat Amid Steady SelfStorage Demand
BofA Lifts Pfizer Price Target Following Strong Q1 Performance
FSV Q1 2026 Earnings EPS Beats Estimates by 63 Amid Mixed Market Sentiment
Cadrenal Therapeutics CVKD Slides 52 as Support Level Comes into Focus